|Day Low/High||149.17 / 153.36|
|52 Wk Low/High||125.84 / 197.00|
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.
Botox maker Allergan's CEO is pushing back against activist investors and may get help from the company's latest earnings report.
Recent moves in industrial stocks demonstrate the importance of buying hated stock/groups when your conviction is high.
The drug giant beat analyst expectations for Q2 and issued positive guidance for the rest of the year.
Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.
U.S. stock futures are mixed as investors react with caution to a broadly worded trade truce between the European Union and the United States; Facebook tanks as the social media giant points to slower growth; AMD swings to a profit; Qualcomm scraps deal for NXP.
Jim Cramer uses PepsiCo's earnings, which crushed analysts' expectations, to illustrate why investors need to do their own homework to find real winners.
Aegon today announces that it has signed an agreement to expand its successful partnership with Banco Santander in Spain.
It's every investor's dream to find a stock that goes up at least 1,000%; here are a few that did.
Shareholders were given the opportunity to choose between receiving the 2017 final dividend of EUR 0.
We are looking to buy into weakness today, even though the market has gotten significantly tougher over the past few days.
Today, at Aegon's first interactive webinar for analysts and investors, CFO Matt Rider will detail the company's ongoing actions to deliver on its financial transformation, approach to capital management and prioritization in capital deployment.
Don't count on it. The fundamentals paint two very different pictures, Cramer says.
Jim discusses Comcast's offer for Fox, Kohl's, Amazon, 3M, JPMorgan, Goldman Sachs, Citigroup and more!
Markets look calm, but we're seeing some extraordinary breakouts, says Jim Cramer.
You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.
We exited one stock, entered another, raised our price target on Kohl's and downgraded Nordstrom.
A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.
Stocks finished mixed on Thursday as concerns mount over the potential for a major rift on trade and tariffs when G-7 leaders meet later this week.
U.S. stock futures are higher on Thursday and stocks in Europe and Asia extend gains; Jamie Dimon and Warren Buffett urge companies to consider no longer providing quarterly earnings guidance.
As futures point higher, these are the headlines you need to get up to speed during your morning commute.
Tech and retail gains aren't enough to lead markets to new highs.
Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.
Jim discusses our decision to exit Allergan, the AAP Bullpen, Apple's upcoming Worldwide Developers Conference and more!
After a lot of patience and disappointment, we are closing our remaining small 'spec' position.
They may not get all the attention, but antibiotic drugs are increasingly important.
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.